CJC-1295: what the long-acting GHRH analog actually does, and what it doesn't

CJC-1295 is a synthetic, structurally modified version of growth hormone-releasing hormone. Specifically, it's based on the first 29 amino acids of native GHRH, which is the biologically active fragment. It was developed in the early 2000s by a Montreal company called ConjuChem ^[1], and the molecule that got studied in human trials carries an extra piece of chemistry called a Drug Affinity Complex, or DAC. That detail matters more than it sounds, and we'll come back to it.

Functionally, CJC-1295 is a growth hormone secretagogue: a compound that prompts the pituitary to release more of its own GH rather than supplying GH from outside. The intended effect is to push the GH/IGF-1 axis upward without the supraphysiological spikes you get from injecting recombinant human growth hormone.

It's not approved for any human indication, anywhere. There's no NDA, no European authorization, no monograph in the US Pharmacopeia.

Growth hormone-releasing hormone is a 44-amino-acid peptide made in the hypothalamus ^[2]. It travels a short distance through the hypophyseal portal system to the anterior pituitary, where it binds the GHRH receptor on somatotroph cells and tells them to release GH in pulses. The pulses are the point. GH secretion in healthy adults is bursty, mostly nocturnal, and the pulsatility itself appears to matter for how downstream tissues respond.

GH released into circulation then hits hepatic GH receptors, switches on the JAK2-STAT5 pathway, and drives liver production of insulin-like growth factor-1. IGF-1 is the workhorse hormone for most of what people associate with "growth hormone effects," including anabolism, tissue repair, and context-dependent effects on lipolysis and glucose handling. It signals through PI3K/Akt/mTOR and MAPK/ERK, the same cascades that govern cell growth more broadly.

"Native GHRH has a very short half-life of just a few minutes." Dipeptidyl peptidase IV chews it up almost immediately. This is the problem CJC-1295 was designed to solve.

CJC-1295 makes two changes to GHRH 1-29 ^[3].

The first is a set of amino acid substitutions at positions 2, 8, 15, and 27 ^[4]. These positions are where DPP-IV and other proteases prefer to cleave the molecule, so swapping in resistant residues blocks the degradation pathway. By itself, this modification gets you a peptide with a half-life of about 30 minutes ^[5], roughly tenfold longer than native GHRH but still short.

The second change is the DAC: a maleimido-derivatized lysine attached at the C-terminus ^[6]. Once injected, this group reacts covalently with a cysteine residue on circulating serum albumin. The peptide is now bonded to a 66 kDa protein that the kidneys won't filter and proteases won't easily reach ^[7].

The result is dramatic. "In the Phase 1 trial, CJC-1295 with DAC had an estimated half-life of approximately 8 days in humans." Native GHRH lasts minutes; this lasts a workweek.

This is the single most important thing to understand about CJC-1295, and the wellness internet routinely conflates it.

There are two molecules sold under the CJC-1295 name:

CJC-1295 with DAC. The original ConjuChem compound. Albumin-bound, half-life of roughly a week, produces sustained elevation of GH and IGF-1 levels for many days. This is what was tested by Teichman and colleagues in 2006 ^[8]. When pharmacology papers say "CJC-1295," they almost always mean this.

CJC-1295 without DAC, also called Modified GRF 1-29 or Mod GRF 1-29. Same amino acid substitutions, but no albumin tether. Half-life around 30 minutes. Produces a discrete pulse of GH release, then clears. This is what most peptide forums actually recommend, often without naming the distinction.

The pharmacological profiles are not similar. They're different drugs that share a backbone.

A weekly injection of the DAC form keeps GHRH-receptor stimulation tonically elevated for days. A nightly injection of Mod GRF 1-29 produces a single sharp pulse and then disappears. Proponents of the no-DAC form argue this better mimics physiological GH secretion, since native pulsatility is preserved. Proponents of the DAC form argue convenience and sustained IGF-1 elevation. Whether sustained, non-pulsatile GH-axis stimulation is a feature or a problem is, in our reading, the central unanswered question about this molecule.

The receptor-level story is well established. CJC-1295 binds the GHRH receptor on pituitary somatotrophs. Receptor binding activates Gs proteins, raises intracellular cAMP, activates protein kinase A, and triggers transcription of the GH gene plus secretion of stored GH from vesicles.

Downstream, released GH does the things GH does: hepatic IGF-1 production via JAK2-STAT5, peripheral lipolysis, opposition of insulin's effects on glucose, and a long list of anabolic and metabolic actions mediated mostly by IGF-1 acting through PI3K/Akt/mTOR.

The mechanism is not in dispute. What's contested is whether elevating this axis in healthy adults for cosmetic or performance reasons produces the outcomes people are buying it for, and at what cost.

Short answer: very little, and almost all of it from a single 2006 paper.

The Teichman trial, published in the Journal of Clinical Endocrinology & Metabolism, PMID 16352683 ^[9], remains the foundational and essentially only controlled human study of CJC-1295. It was a pair of ascending-dose, placebo-controlled Phase 1 studies in healthy adults aged 21 to 61, testing subcutaneous doses of 30, 60, 125, or 250 µg/kg ^[10].

The pharmacokinetic results were the headline. A single injection raised mean plasma GH two- to tenfold for at least six days ^[11]. Mean IGF-1 climbed 1.5- to threefold and stayed elevated for nine to eleven days ^[12]. With repeated dosing, IGF-1 remained above baseline for up to 28 days ^[13]. No serious adverse events were reported. The 30-60 µg/kg range was best tolerated ^[14].

That's the entire controlled human efficacy and safety dataset. One trial. Roughly two dozen subjects. "Up to several weeks of observation."

Everything else is supporting evidence of a much weaker kind. Sackmann-Sala and colleagues published a small serum-protein analysis in 2009 showing GH/IGF-1 axis activation in normal subjects ^[15], useful but not replicated at scale. "Van Hout and Hearne's 2016 paper in Substance Use & Misuse is a netnography of bodybuilding forum threads on female self-administration"; it documents what users report, not what the drug does. "Three 2026 narrative reviews — Mayfield et al. in AJSM, Rahman et al. in the JAAOS Global Research & Reviews, and a systematic review on peptides published in IJMS" reach the same conclusion in slightly different language: the preclinical work is interesting, the human trial data are insufficient, and the orthopaedic and sports-medicine claims circulating around CJC-1295 lack controlled validation ^[16].

No Phase 2 trial. No Phase 3 trial. No long-term outcome data on body composition, bone density, cardiovascular endpoints, or cancer incidence.

When peptide marketers say CJC-1295 is "clinically studied," this is what they mean.

The animal work is more reassuring on mechanism than on safety. Alba and colleagues showed in 2006 that daily CJC-1295 normalized growth and GH/IGF-1 levels in GHRH-knockout mice ^[17]. That confirms the molecule does what it's designed to do at a receptor level. It doesn't tell you what happens when a 45-year-old with normal endocrine function injects it weekly for two years.

This is the structural limitation of the preclinical literature here. Knockout models test whether a drug can rescue deficiency. They don't test whether stimulating an already-functioning axis is safe over time, which is the actual question for the population using CJC-1295.

Forum and clinic-marketing claims for CJC-1295 cluster into a familiar set: increased lean mass, reduced body fat, better sleep, faster recovery, improved skin, sharper cognition, "anti-aging" effects in general. The Van Hout and Hearne forum analysis captures most of these, plus female-specific use cases around physique and skin.

Some of these claims are mechanistically plausible. IGF-1 does promote tissue repair, GH does affect sleep, and lipolysis is a real GH effect. Mechanistically plausible is not the same as shown.

Sleep is the most interesting case. There's reasonable physiological rationale for thinking GH-axis stimulation could improve slow-wave sleep, because endogenous GH pulses are tied to deep sleep. Whether weekly CJC-1295 with DAC actually does this in a placebo-controlled comparison, nobody has tested.

What the data support, narrowly:

CJC-1295 with DAC raises GH and IGF-1 for days after a single injection, in healthy adults, over the time window of a Phase 1 trial. The pharmacokinetics are real. The albumin-binding strategy works as designed.

What the data don't support:

Specific body-composition claims, durable improvements in lean mass or fat mass beyond a few weeks, sleep-architecture changes, injury-healing acceleration, cognitive benefits, or any "anti-aging" outcome in the meaningful sense of altered disease incidence or biological age markers. None of this has been tested in controlled trials. The marketing runs ahead of the data.

The honest position is that CJC-1295 demonstrably moves a hormonal axis and plausibly produces downstream effects of GH and IGF-1 elevation. Whether those effects are net beneficial in healthy adults, and at what dose, for how long, with what tradeoffs, is genuinely unknown.

The rationale for stacking CJC-1295 with ipamorelin is mechanistic and, on its face, reasonable. CJC-1295 binds the GHRH receptor; ipamorelin binds the ghrelin/GHSR-1a receptor. These are two distinct pituitary signals for GH release, and combined stimulation produces a synergistic GH pulse larger than either compound alone, at least in the older GHRH-plus-GHRP literature that Veldhuis and Bowers reviewed in 2009 ^[18].

The mechanistic case is plausible. The human evidence specific to CJC-1295 plus ipamorelin is essentially absent. No published RCT studies this combination as of mid-2026. The dosing protocols you see circulated, CJC-1295 no-DAC at 100-300 µg with ipamorelin at 150-300 µg, subcutaneous, often at night, are extrapolated from compound-specific data and forum consensus, not from controlled trials of the combination itself.

The reason the stack is everywhere is partly mechanistic and partly commercial. Compounding pharmacies that prepared one tended to prepare the other; the bundle made marketing sense.

Direct safety data on CJC-1295 in humans comes from the Teichman trial and the FDA's adverse-event reporting database. Neither is enough to characterize a chronic-use safety profile.

The Phase 1 trial reported mild injection-site reactions, occasional local urticaria, and no serious adverse events at any tested dose over 49 days. Best tolerated in the 30-60 µg/kg range.

"FAERS - the FDA's voluntary post-market reporting system - contains reports of chronic kidney disease tied to CJC-1295, as well as reports flagged as "drug ineffective."" These numbers carry the usual caveats: FAERS is uncontrolled, voluntary, doesn't establish causation, and reflects off-label and unsupervised use. They're signals to watch, not conclusions.

The theoretical and class-related risks are where the conversation gets serious.

IGF-1 and cancer biology. Sustained elevation of IGF-1 has been associated, epidemiologically, with increased risk of prostate cancer in older men and inconsistently with colorectal cancer. The UK's Committee on Carcinogenicity reviewed the IGF-1 literature in 2018 and concluded the evidence is mixed but not dismissible ^[19]. The absolute risk increment at the IGF-1 levels CJC-1295 produces is not characterized. The mechanism, IGF-1 as a growth and anti-apoptotic signal acting through PI3K/Akt, is well established in tumor biology.

Insulin resistance. GH is a counter-regulatory hormone to insulin. Acromegalic patients develop insulin resistance and diabetes at elevated rates. Whether sustained sub-acromegalic GH elevation from weekly CJC-1295 produces clinically relevant glucose dysregulation in healthy adults over months or years is untested.

Fluid retention, carpal tunnel, arthralgias. Standard GH-excess effects, documented with recombinant GH therapy. Not specifically reported for CJC-1295 at therapeutic doses, but the class concern is real.

Pituitary desensitization. This one is theoretical and specific to the DAC form. The somatotroph axis evolved to respond to pulsatile GHRH. Tonically elevated GHRH-receptor stimulation could, in principle, downregulate the receptor or alter somatotroph responsiveness. Nobody has studied this past seven weeks.

The fundamental safety issue is the gap. Twenty-eight to forty-nine days of Phase 1 observation is not a basis for inferring what happens at three years.

The regulatory file is messy and active. The short version:

CJC-1295 is not FDA-approved. It has never been approved. The compounding pathway, the route by which 503A pharmacies could legally prepare it for individual patients, is currently closed, with caveats.

The longer version, which matters because the situation is still moving:

In 2023 and into 2024, FDA placed CJC-1295 on the Category 2 bulk substances list ^[20], meaning the agency had identified real safety concerns or insufficient evidence to allow compounding. In September 2024, the nominators withdrew their nominations and FDA removed the compound from Category 2 ^[21], instead referring all CJC-1295 forms (free base, acetate, DAC variants) to the Pharmacy Compounding Advisory Committee for formal review.

PCAC met on December 4, 2024 ^[22]. FDA's position at that meeting was that CJC-1295 DAC free base, DAC acetate, and DAC trifluoroacetate shouldn't be included on the 503A Bulks List ^[23]. In April 2026, FDA formally removed CJC-1295 from Category 2 alongside several other peptides ^[24], leaving it in a regulatory gray zone: not explicitly prohibited, not authorized for compounding either.

What this means in practice: licensed compounding pharmacies in the US can't prepare CJC-1295 for patient-specific use under standard 503A rules, because it isn't on the bulks list that authorizes such compounding. CJC-1295 sold as a "research chemical," the dominant channel, comes with "not for human use" labeling that doesn't confer any legal authorization for clinical administration. WADA bans it for competitive athletes ^[25].

Sermorelin, which is GHRH 1-29 itself and has a settled regulatory history, remains a legal compoundable alternative. It has a much shorter half-life and produces only acute, short-lived GHRH-receptor stimulation. Tesamorelin, another stabilized GHRH analog, is FDA-approved for HIV-associated lipodystrophy ^[26] and is the only GHRH-axis drug in this family that has cleared a Phase 3 program for a defined indication.

A July 2026 FDA advisory committee meeting is scheduled to revisit possible inclusion of select peptides on the 503A bulks list ^[27]. Whether CJC-1295 will be on that agenda isn't confirmed in publicly available materials.

What we know:

CJC-1295 with DAC reliably elevates GH and IGF-1 for days after a single injection in healthy adults. The pharmacokinetics, established in a 2006 Phase 1 trial of about two dozen subjects, are not seriously contested. The molecule does what its designers intended at the receptor level.

What we don't know:

Whether weeks or months of sustained, non-pulsatile GH-axis stimulation produces meaningful clinical outcomes in body composition, sleep, recovery, or longevity markers has not been tested in controlled human studies. Whether it's safe over years has not been tested. Whether the DAC form's tonic stimulation differs from the no-DAC form's pulsatile stimulation in clinically important ways is mechanistically plausible and empirically unaddressed.

The honest framing is that CJC-1295 is a pharmacologically interesting molecule with a wellness-market footprint that vastly exceeds its clinical-evidence footprint. The Phase 1 data are real. The Phase 2 data don't exist. The Phase 3 data don't exist. The long-term safety data don't exist.

For readers researching this compound, the gap between what's claimed and what's shown is not a small one. It's most of the picture.